Trial Profile
Double-Blind, Placebo-Controlled Proof of Concept Study in Youth With Fragile X Syndrome
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 04 Feb 2021
Price :
$35
*
At a glance
- Drugs Acamprosate (Primary)
- Indications Fragile X syndrome
- Focus Proof of concept; Therapeutic Use
- 01 Feb 2021 Status changed from active, no longer recruiting to completed.
- 03 Mar 2020 Planned primary completion date changed from 1 Jun 2019 to 1 Jun 2020.
- 08 Feb 2019 Planned End Date changed from 1 Feb 2018 to 1 Jun 2020.